Industry News (Genetics)

Company Licenses Recent Alzheimer's Discoveries

Published in Gene Therapy Weekly, March 15th, 1999

GenoPlex, Inc., Denver, Colorado, announced that it has entered into an exclusive license arrangement with Massachusetts General Hospital for discoveries by Harvard neurogeneticist, Dr. Rudolph Tanzi, related to A2M gene variants genetically linked to Alzheimer's disease.

The A2M genes code for variants of the protein a2-macroglobulin (a2M). A2M is only the second gene found to be a risk factor for developing late-onset Alzheimer's disease (AD); late-onset accounts for the vast majority of Alzheimer's cases. One of the a2M variants is found in approximately 30 percent of the U.S. population, the other in 42 percent. Thus, these variants could play a significant role...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1999-03-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry